Evaluation of the bioavailability of a Tamiflu taste-masking pediatric formulation using a juvenile pig model and LC-MS/MS

References

• Wenger TL, Stern WC. The cardiovascular profile of bupropion. J Clin Psychiatry. 1983;44(5):176–182.
   PubMed Web of Science ®Google Scholar
• Pein M, Preis M, Eckert C, Kiene FE. Taste-masking assessment of solid oral dosage forms–a critical review. Int J Pharm. 2014;465(1–2):239–254. doi:10.1016/j.ijpharm.2014.01.036
   PubMed Web of Science ®Google Scholar
• Areeg Anwer Ali NAC, Daud Baraka Abdallah. Pediatric drug development: formulation considerations. Drug Development and Industrial Pharmacy. 2014;40(10):1283–1299. doi:10.3109/03639045.2013.850713
   PubMed Web of Science ®Google Scholar
• Thabet Y, Klingmann V, Breitkreutz J. Drug formulations: standards and novel strategies for drug administration in pediatrics. J Clin Pharmacol. 2018;58(Suppl. 10):S26–S35. doi:10.1002/jcph.1138
   PubMed Web of Science ®Google Scholar
• Strickley RG. Pediatric oral formulations: an updated review of commercially available pediatric oral formulations since 2007. J Pharm Sci. 2019;108(4):1335–1365. doi:10.1016/j.xphs.2018.11.013
   PubMed Web of Science ®Google Scholar
• Arima H, Higashi T, Motoyama K. Improvement of the bitter taste of drugs by complexation with cyclodextrins: applications, evaluations and mechanisms. Ther Deliv. 2012;3(5):633–644. doi:10.4155/tde.12.28
   PubMedGoogle Scholar
• D'Sa S. Multidisciplinary bedside notes: an experiment in care. Nurs Times. 1995;91(12):46–47.
   PubMedGoogle Scholar
• Ivanovska V, Rademaker CM, van Dijk L, Mantel-Teeuwisse AK. Pediatric drug formulations: a review of challenges and progress. Pediatrics. 2014;134(2):361–372. doi:10.1542/peds.2013-3225
   PubMed Web of Science ®Google Scholar
• Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev Ind Pharm. 2004;30(5):429–448. doi:10.1081/DDC-120037477
   PubMed Web of Science ®Google Scholar
• Frange P, Avettand-Fenoel V, Blanche S. Poor palatability of the new ritonavir formulation is a major obstacle to adherence to treatment in young children. J Antimicrob Chemother. 2018;73(5):1435–1437. doi:10.1093/jac/dky029
   PubMed Web of Science ®Google Scholar
• Douroumis D. Practical approaches of taste masking technologies in oral solid forms. Expert Opin Drug Deliv. 2007;4(4):417–426. doi:10.1517/17425247.4.4.417
   PubMed Web of Science ®Google Scholar
• Sohail Arshad M, Zafar S, Yousef B, et al. A review of emerging technologies enabling improved solid oral dosage form manufacturing and processing. Advan Drug Deliv Rev. 2021;178:113840. doi:10.1016/j.addr.2021.113840
   PubMed Web of Science ®Google Scholar
• Vishvakarma V, Kaur M, Nagpal M, Arora S. Role of nanotechnology in taste masking: recent updates. Curr Drug Res Rev. 2023;15(1):1–14. doi:10.2174/2589977514666220526091259
   PubMedGoogle Scholar
• Zhang W, Li G, Xiao C, et al. Mesoporous silica carrier-based composites for taste-masking of bitter drug: fabrication and palatability evaluation. AAPS PharmSciTech. 2022;23(2):75. doi:10.1208/s12249-018-1222-x
   PubMed Web of Science ®Google Scholar
• Hu S, Liu X, Zhang S, Quan D. An overview of taste-masking technologies: approaches, application, and assessment methods. AAPS PharmSciTech. 2023;24(2):67. doi:10.1208/s12249-023-02520-z
   PubMed Web of Science ®Google Scholar
• Fan Y, Chen H, Huang Z, et al. Taste-masking and colloidal-stable cubosomes loaded with Cefpodoxime proxetil for pediatric oral delivery. Inter J Pharmaceut. 2020;575:118875. doi:10.1016/j.ijpharm.2019.118875
   PubMed Web of Science ®Google Scholar
• Bianchin MD, Prebianca G, Immich MF, et al. Monoolein-based nanoparticles containing indinavir: a taste-masked drug delivery system. Drug Develop Indust Pharm. 2021;47(1):83–91. doi:10.1080/03639045.2020.1862167
   PubMed Web of Science ®Google Scholar
• Zhu C, Chen J, Shi L, et al. Development of child-friendly lisdexamfetamine chewable tablets using ion exchange resin as a taste-masking carrier based on the concept of quality by design (QbD). AAPS PharmSciTech. 2023;24(5):132. doi:10.1208/s12249-023-02592-x
   PubMed Web of Science ®Google Scholar
• Kalra A, Bhat P, Kaur IP. Deciphering molecular mechanics in the taste masking ability of Maltodextrin: developing pediatric formulation of Oseltamivir for viral pandemia. Carbohydr Polym. 2021;260:117703. doi:10.1016/j.carbpol.2021.117703
   PubMed Web of Science ®Google Scholar
• Atemnkeng MA, De Cock K, Plaizier-Vercammen J. Post-marketing assessment of content and efficacy of preservatives in artemisinin-derived antimalarial dry suspensions for paediatric use. Malar J. 2007;6:12. doi:10.1186/1475-2875-6-12
   PubMed Web of Science ®Google Scholar
• Rahman Z, Zidan AS, Berendt RT, Khan MA. Tannate complexes of antihistaminic drug: sustained release and taste masking approaches. Int J Pharm. 2012;422(1–2):91–100. doi:10.1016/j.ijpharm.2011.10.033
   PubMedGoogle Scholar
• Siddiqui A, Shah RB, Khan MA. Oseltamivir phosphate-amberlite(TM) IRP 64 ionic complex for taste masking: preparation and chemometric evaluation. J Pharm Sci. 2013;102(6):1800–1812. doi:10.1002/jps.23518
   PubMed Web of Science ®Google Scholar
• Roth WJ, Kissinger CB, McCain RR, et al. Assessment of juvenile pigs to serve as human pediatric surrogates for preclinical formulation pharmacokinetic testing. AAPS J. 2013;15(3):763–774. doi:10.1208/s12248-013-9482-6
   PubMed Web of Science ®Google Scholar
• Lindegardh N, Hien TT, Farrar J, Singhasivanon P, White NJ, Day NP. A simple and rapid liquid chromatographic assay for evaluation of potentially counterfeit Tamiflu. J Pharm Biomed Anal. 2006;42(4):430–433. doi:10.1016/j.jpba.2006.04.028
   PubMed Web of Science ®Google Scholar
• Joseph-Charles J, Geneste C, Laborde-Kummer E, Gheyouche R, Boudis H, Dubost JP. Development and validation of a rapid HPLC method for the determination of oseltamivir phosphate in Tamiflu and generic versions. J Pharm Biomed Anal. 2007;44(4):1008–1013. doi:10.1016/j.jpba.2007.04.002
   PubMed Web of Science ®Google Scholar
• Bahrami G, Mohammadi B, Kiani A. Determination of oseltamivir carboxylic acid in human serum by solid phase extraction and high performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;864(1–2):38–42. doi:10.1016/j.jchromb.2008.01.048
   PubMed Web of Science ®Google Scholar
• Fuke C, Ihama Y, Miyazaki T. Analysis of oseltamivir active metabolite, oseltamivir carboxylate, in biological materials by HPLC-UV in a case of death following ingestion of Tamiflu. Leg Med (Tokyo). 2008;10(2):83–87. doi:10.1016/j.legalmed.2007.07.003
   PubMedGoogle Scholar
• Green MD, Nettey H, Wirtz RA. Determination of oseltamivir quality by colorimetric and liquid chromatographic methods. Emerg Infect Dis. 2008;14(4):552–556. doi:10.3201/eid1404.061199
   PubMed Web of Science ®Google Scholar
• Narasimhan B, Abida K, Srinivas K. Stability indicating RP-HPLC method development and validation for oseltamivir API. Chem Pharm Bull (Tokyo). 2008;56(4):413–417. doi:10.1248/cpb.56.413
   PubMed Web of Science ®Google Scholar
• Eisenberg EJ, Cundy KC. High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde. J Chromatogr B Biomed Sci Appl. 1998;716(1–2):267–273. doi:10.1016/S0378-4347(98)00268-0
   PubMedGoogle Scholar
• Zeynep Aydoğmuş SÇ, Sıdıka Toker. RP-HPLC method for determination of oseltamivir phosphate in capsules and spiked plasma. Analyt Lett. 2010;43(14):2200–2209. doi:10.1080/00032711003698721
   Web of Science ®Google Scholar
• Jabbaribar F, Mortazavi A, Jalali-Milani R, Jouyban A. Analysis of oseltamivir in Tamiflu capsules using micellar electrokinetic chromatography. Chem Pharm Bull (Tokyo). 2008;56(12):1639–1644. doi:10.1248/cpb.56.1639
   PubMed Web of Science ®Google Scholar
• Laborde-Kummer E, Gaudin K, Joseph-Charles J, Gheyouche R, Boudis H, Dubost JP. Development and validation of a rapid capillary electrophoresis method for the determination of oseltamivir phosphate in Tamiflu and generic versions. J Pharm Biomed Anal. 2009;50(3):544–546. doi:10.1016/j.jpba.2009.05.016
   PubMed Web of Science ®Google Scholar
• Wiltshire H, Wiltshire B, Citron A, et al. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B Biomed Sci Appl. 2000;745(2):373–388. doi:10.1016/S0378-4347(00)00300-5
   PubMedGoogle Scholar
• Lindegardh N, Hanpithakpong W, Wattanagoon Y, Singhasivanon P, White NJ, Day NP. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;859(1):74–83. doi:10.1016/j.jchromb.2007.09.018
   PubMed Web of Science ®Google Scholar
• Heinig K, Bucheli F. Sensitive determination of oseltamivir and oseltamivir carboxylate in plasma, urine, cerebrospinal fluid and brain by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;876(1):129–136. doi:10.1016/j.jchromb.2008.10.037
   PubMed Web of Science ®Google Scholar
• Hooff GP, Meesters RJ, van Kampen JJ, et al. Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate–a validated assay for the clinic. Anal Bioanal Chem. 2011;400(10):3473–3479. doi:10.1007/s00216-011-5050-z
   PubMed Web of Science ®Google Scholar
• Kanneti R, Bhavesh D, Paramar D, R S, Bhatt PA. Development and validation of a high-throughput and robust LC-MS/MS with electrospray ionization method for simultaneous quantitation of oseltamivir phosphate and its oseltamivir carboxylate metabolite in human plasma for pharmacokinetic studies. Biomed Chromatogr. 2011;25(6):727–733. doi:10.1002/bmc.1509
   PubMed Web of Science ®Google Scholar
• Berendsen BJ, Wegh RS, Essers ML, Stolker AA, Weigel S. Quantitative trace analysis of a broad range of antiviral drugs in poultry muscle using column-switch liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem. 2012;402(4):1611–1623. doi:10.1007/s00216-011-5581-3
   PubMed Web of Science ®Google Scholar
• Liu Z, Yang F, Yao M, Lin Y, Su Z. Simultaneous determination of antiviral drugs in chicken tissues by ultra high performance liquid chromatography with tandem mass spectrometry. J Sep Sci. 2015;38(10):1784–1793. doi:10.1002/jssc.201401461
   PubMed Web of Science ®Google Scholar
• Mu P, Xu N, Chai T, et al. Simultaneous determination of 14 antiviral drugs and relevant metabolites in chicken muscle by UPLC-MS/MS after QuEChERS preparation. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;17(23):1023–1024. doi:10.1016/j.jchromb.2016.04.036
   Google Scholar
• FDA Guidance for Industry. Bioanalytical Method Validation. [ May 2018]. https://www.fda.gov/media/70858/download
   Google Scholar